EIGRQ

Eiger BioPharmaceuticals Inc

USOTC

Add Alert

EIGRQ

Eiger BioPharmaceuticals Inc

USOTC

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

Renee

04/10/24 6:23 PM

Post #1,047

EIGR changed to EIGRQ, bankruptcy. Delisted from the Nasdaq to the OTC: ***PPS at $1.72 in after hours.

https://otce.finra.org/otce/dailyList?viewType=Additions

2020trader Free

04/10/24 1:36 AM

Post #1,046

down 10% today, expecting lower

2020trader Free

04/06/24 12:07 AM

Post #1,045

down 4% today

2020trader Free

04/04/24 8:57 PM

Post #1,044

expecting lower

Awl416

04/01/24 11:19 AM

Post #1,043

Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection

Awl416

04/01/24 10:25 AM

Post #1,042

Uh oh

Disquisition Free

01/07/24 11:40 PM

Post #1,041

INDEFATIGABLE DUMPING

glenn1919

10/21/23 8:13 AM

Post #1,040

Re: #1,039: @glenn1919 - EIGR.......................................https://stockcharts.com/h-sc/ui?s=EIG

EIGR............................................https://stockcharts.com/h-sc/ui?s=EIGR&p=W&b=5&g=0&id=p86431144783

glenn1919

10/07/23 9:09 AM

Post #1,039

EIGR.......................................https://stockcharts.com/h-sc/ui?s=EIGR&p=W&b=5&g=0&id=p86431144783

Monksdream PremiumMember

09/13/23 1:35 PM

Post #1,038

EIGR new 52 week low

Triple nickle Free

06/30/23 11:07 AM

Post #1,037

Hmmm

Disquisition Free

12/14/22 5:03 PM

Post #1,036

HORRENDOUS DUMPING

make it happen Free

03/30/22 9:41 AM

Post #1,035

Re: #1,029: @make it happen - Literally losing over $440,000,000 million a year with

$50,000,000 share offering. This is adding approximately 1/6 the structure. Decent dilution still not enough to keep the doors open for a year.

TrendTrade2016 PremiumMember

03/23/22 10:12 AM

Post #1,034

Re: #1,029: @make it happen - Literally losing over $440,000,000 million a year with

lol

TrendTrade2016 PremiumMember

03/22/22 12:16 PM

Post #1,033

Re: #1,028: @make it happen - Volume is not sustainable imo and did a

Nice analysis

TrendTrade2016 PremiumMember

03/21/22 11:59 AM

Post #1,032

Re: #1,029: @make it happen - Literally losing over $440,000,000 million a year with

lmao

TrendTrade2016 PremiumMember

03/21/22 11:45 AM

Post #1,031

monster rare drug play

TrendTrade2016 PremiumMember

03/21/22 11:19 AM

Post #1,030

very nice push coming....rare disease drugs are expensive!!

make it happen Free

03/17/22 11:16 AM

Post #1,029

Literally losing over $440,000,000 million a year with only 3.4 mil revenue... Covid is a semi thing of the past now. This has potential to do a reverse split again imho in a year or 2. Not bashing but financials can't add up like this. Hi I'm spending half a Billion dollars a year and have basically zero revenue. Where's this going to come from to keep it going?

make it happen Free

03/17/22 10:33 AM

Post #1,028

Re: #1,027: @TrendTrade2016 - watch and learn loser

Volume is not sustainable imo and did a 15 to 1 Reverse split. They don't even have enough cash to cover 1 quarter. Was $0.86

TrendTrade2016 PremiumMember

03/17/22 10:28 AM

Post #1,027

Re: #1,026: @make it happen - Mid tripple digit negative profitability over 600% NEGATIVE.

watch and learn loser

make it happen Free

03/17/22 9:43 AM

Post #1,026

Mid tripple digit negative profitability over 600% NEGATIVE. I don't think I have ever seen such big negative numbers on any ticker my entire life. While burning over $110,000,000 million a quarter... with revenues of 3 mil..

Profitability
Profit Margin -279.34%
Operating Margin (ttm) -633.66%

Management Effectiveness
Return on Assets (ttm) -35.62%
Return on Equity (ttm) -40.51%

Income Statement
Revenue (ttm) 12.14M
Revenue Per Share (ttm) 0.36
EBITDA -76.66M
Net Income Avi to Common (ttm) -33.92M
Diluted EPS (ttm) -1.00

Cash Flow Statement
Operating Cash Flow (ttm) -71.34M
Levered Free Cash Flow (ttm) -41.5M

TrendTrade2016 PremiumMember

03/17/22 9:37 AM

Post #1,025

EIGR monster

TrendTrade2016 PremiumMember

03/17/22 9:03 AM

Post #1,024

massive bio play taking off in pre!

ae kusterer Free

02/08/21 8:50 PM

Post #1,023

jhpratt@alphavestcapital.com is my email.Please email me insights into eigr.

alphavestcapital.com

MOST IMPORTANT SUMMARY SENTENCES IN THE LANCET ARTICLE:(paraphrased: EIGR’s interferon works better than monoclonal antibodies at reducing covid viral load.Plus, EIGR’s interferon can be administered on an outpatient basis. )"Added value of this study This study shows that a single subcutaneous injection of 180 µg peginterferon lambda has an antiviral effect in outpatients with COVID-19. The decline in viral load was greater with peginterferon lambda treatment than with placebo. The more rapid viral load decline and higher clearance rate were most pronounced in those with high viral loads, a finding also reported with monoclonal antibody therapies in patients with COVID-19. However, the magnitude of the viral load decline compared with that of placebo was much greater with peginterferon lambda than has been reported with monoclonal antibody therapies to date. Peginterferon lambda was safe and well tolerated in outpatients with mild-to-moderate COVID-19, with a similar side-effect profile to that of placebo and no concerning laboratory adverse events. Implications of all the available evidence No approved therapy exists for outpatients with COVID-19. This study showed that peginterferon lambda accelerated viral clearance, particularly in those with high baseline viral loads, highlighting the importance of quantitative viral load testing in the assessment of antiviral agents for patients with COVID-19. Treatment early in the course of disease might prevent clinical deterioration and shorten the duration of viral shedding, which might have an important public health effect by reducing transmission and reducing the duration of self-isolation."

Penny chatter Free

11/23/20 8:57 AM

Post #1,022

Re: #1,021: @TheFinalCD - more NEWS https://ih.advfn.com/stock-market/NASDAQ/eiger-biopharmaceuticals-EIGR

Dead though lol

TheFinalCD PremiumMember

11/23/20 8:53 AM

Post #1,021

Re: #1,015: @Penny chatter - Folks miss the covid implications here and they

more NEWS https://ih.advfn.com/stock-market/NASDAQ/eiger-biopharmaceuticals-EIGR/stock-news/83743438/eiger-biopharmaceuticals-sells-priority-review-vou

Oger

11/22/20 11:01 PM

Post #1,020

Re: #1,019: @Penny chatter - They say the right things in the conference

Let’s go over $20...

Penny chatter Free

11/22/20 10:41 PM

Post #1,019

Re: #1,018: @Oger - You think this rocks tomorrow penny chatter?

They say the right things in the conference call it should go bananas. The drug does have covid implications https://twitter.com/Goldbarstocks/status/1330608767055106048?s=19

Oger

11/22/20 10:37 PM

Post #1,018

Re: #1,017: @Penny chatter - Think someone will be stated it. I looked

You think this rocks tomorrow penny chatter?

Penny chatter Free

11/22/20 10:35 PM

Post #1,017

Re: #1,016: @Oger - Who’s the buyer?

Think someone will be stated it. I looked and couldn't find it

Oger

11/22/20 10:33 PM

Post #1,016

Re: #1,015: @Penny chatter - Folks miss the covid implications here and they

Who’s the buyer?
I couldn’t find it...

Penny chatter Free

11/22/20 6:24 PM

Post #1,015

Re: #1,010: @TheFinalCD - https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment

Folks miss the covid implications here and they already have a buyer here https://twitter.com/Goldbarstocks/status/1330608767055106048?s=19

Oger

11/21/20 11:16 AM

Post #1,014

Re: #1,013: @Penny chatter - I agree as it has 80% institutional ownership

It will sink it the magnitude of this drug, extending the life of these
children 2-1/2 years ....

Penny chatter Free

11/21/20 9:15 AM

Post #1,013

Re: #1,012: @Oger - Over $20 on Monday......

I agree as it has 80% institutional ownership

Oger

11/20/20 10:11 PM

Post #1,012

Re: #1,009: @Penny chatter - What kind of fda approval don't see interest?

Over $20 on Monday......

Penny chatter Free

11/20/20 7:45 PM

Post #1,011

Re: #1,010: @TheFinalCD - https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment

They didn't have to halt for this lol

TheFinalCD PremiumMember

11/20/20 7:16 PM

Post #1,010

Re: #1,009: @Penny chatter - What kind of fda approval don't see interest?

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-hutchinson-gilford-progeria-syndrome-and-some-progeroid-laminopathies

https://medlineplus.gov/genetics/condition/hutchinson-gilford-progeria-syndrome/

Progeria
Also known as: hutchinson-gilford progeria syndrome
OVERVIEW
SYMPTOMS
DIAGNOSIS
TREATMENT
A progressive genetic disorder where symptoms of aging are manifested at an early age.
How common is condition?
Extremely rare (Fewer than 1,000 cases per year in US)
Is condition treatable?
Treatments can help manage condition, no known cure
Does diagnosis require lab test or imaging?
Requires lab test or imaging
Condition Highlight
Present at birth, onset can be infantile or juvenile
Condition Highlight
May be dangerous or life threatening
Condition Highlight
Family history may increase likelihood

Penny chatter Free

11/20/20 7:12 PM

Post #1,009

Re: #1,007: @TheFinalCD - HALTED PENDING NEWS 11/20/2020 16:53:30 EIGR Eiger BioPharma NASDAQ

What kind of fda approval don't see interest?

Penny chatter Free

11/20/20 6:10 PM

Post #1,008

Re: #1,007: @TheFinalCD - HALTED PENDING NEWS 11/20/2020 16:53:30 EIGR Eiger BioPharma NASDAQ

On it

TheFinalCD PremiumMember

11/20/20 5:00 PM

Post #1,007

Re: #1,006: @Fezziwig2008 - EIGR - Lambda is most paradoxical interferon :

HALTED PENDING NEWS 11/20/2020 16:53:30 EIGR Eiger BioPharma NASDAQ
T1

Fezziwig2008 Free

08/22/20 1:08 PM

Post #1,006

EIGR - Lambda is most paradoxical interferon :
“ IFN-lambda responses to dsRNA in the human infant airway epithelium are regulated by p38-MAPK and NF-kB signaling. High in vivo IFN-lambda production is influenced by virus type and associated with recurrent respiratory sick visits in young children.”

https://scholar.google.com.hk/scholar?start=50&q=interferon+lambda&hl=en&as_sdt=0,33&as_ylo=2020#d=gs_qabs&u=%23p%3DpIKe3q7igMIJ

MWM

08/18/20 9:10 PM

Post #1,005

Re: #1,004: @Fezziwig2008 - EIGR is expected to release interim data from

A mutual friend we have really likes it.

Small share structure is compelling...

Fezziwig2008 Free

08/18/20 8:46 PM

Post #1,004

Re: #1,002: @MWM - $EIGR what is Cooking?

EIGR is expected to release interim data from its Stanford Lambda Trial - I’m not too excited, given the emergent need for any slightly positive data regarding the treatment of SARS2 -see Remdesivir 4 day advantage- and the failure of the data monitoring committee - who already had their interim look/- to halt the study on efficacy - a little bird told me (when I was a vocal advocate of EIGR on Twitter)- that the data was less than compelling to that point weeks ago - certainly that might have changed. The recent insider buy certainly makes on hopeful that it has. A recent seeking alpha pump suggests the upcoming Progeria approval carries tge rest of the pipeline - have you seen how rare Progeria is?

MWM

08/18/20 3:59 PM

Post #1,003

https://seekingalpha.com/instablog/52316800-friar-tuck-esq/5480909-eiger-biopharmaceuticals-low-risk-biotech-10-bagger-near-term-catalyst

MWM

08/18/20 3:49 PM

Post #1,002

Re: #1,000: @Fezziwig2008 - EIGR ”Although no synthetic IFN-lambda is yet FDA-approved,

$EIGR what is Cooking?

MWM

08/10/20 10:02 AM

Post #1,001

Re: #1,000: @Fezziwig2008 - EIGR ”Although no synthetic IFN-lambda is yet FDA-approved,

EIGR is cooking...

Fezziwig2008 Free

08/03/20 10:54 AM

Post #1,000

EIGR ”Although no synthetic IFN-lambda is yet FDA-approved, preliminary results in a clinical trial in hepatitis D patients show that it has the same antiviral potency as type I IFN but is much safer and better tolerated. A study in mice found that synthetic IFN-lambda was as effective as IFN-alpha in treating influenza but didn’t have the same proinflammatory effects.”
https://www.frontiersin.org/articles/10.3389/fneur.2020.00146/full

Fezziwig2008 Free

07/29/20 6:14 AM

Post #999

On EIGR (Lambda is IFN III) “Treatment with type I and III IFNs can dramatically inhibit SARS-CoV-2 replication in primary human airway epithelial cells with the corresponding induction of ISGs.22 The role of type III IFNs in the suppression of virus replication has been highlighted.23,24 Type III IFN shows a better treatment option than type I IFN for influenza A virus-induced disease for its induction of antiviral immunity without the pro-inflammatory responses.”

https://www.biorxiv.org/content/10.1101/2020.07.26.222026v1.full.pdf

Fezziwig2008 Free

07/26/20 4:40 PM

Post #998

EIGR “IFN-Lambda4 showed a strong therapeutic effect in reducing MERS-CoV infection with higher induction of IFN-stimulated genes. Thus, IFN-? has a decisive function in the respiratory epithelium that greatly limits MERS-CoV replication, and may be a key cytokine for better therapeutic outcomes against MERS-CoV infection in respiratory tract.” Success w/1 coronavirus is Promising-awaiting word from Stanford on interim dat in SARS-2 by summer’s end.

https://scholar.google.com/scholar?start=10&q=interferon+lambda&hl=en&as_sdt=0,33&as_ylo=2020#d=gs_qabs&u=%23p%3DG9p7gPGYVVwJ

Older

Eiger BioPharmaceuticals Inc (EIGRQ)

Followers	33	Posters	117
Posts (Today)	0	Posts (Total)	1047
Created	12/03/14	Type	Free
Moderators

Celladon to Merge with Eiger

Celladon Corporation (Nasdaq:CLDN) and Eiger BioPharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which the stockholders of Eiger would become the majority owners of Celladon, and the operations of Celladon and Eiger would be combined. The proposed merger remains subject to certain conditions, including the approval of Celladon stockholders. If approved, upon closing of the transaction, Celladon will be renamed Eiger BioPharmaceuticals, Inc.
An investor syndicate has committed to invest $39.5 million in the combined company including new investors HBM Healthcare Investments, RA Capital Management, Sabby Management, Sphera Global Healthcare, Perceptive Advisors and Monashee Capital Partners together with existing long-time Eiger stockholders, ViVo Capital and InterWest Partners. Six million dollars of the financing has already been funded, and the remaining $33.5 million is expected to close contemporaneously with the completion of the proposed merger. The total cash balance of the combined company upon the closing of the proposed merger and the financing is expected to be greater than $60 million.
The proposed merger will create a clinical-stage company with a diversified development portfolio of product candidates addressing novel targets for four distinct orphan diseases: Hepatitis Delta Virus, bariatric surgery-induced hyperinsulinemic hypoglycemia, pulmonary arterial hypertension, and lymphedema.

http://www.otcmarkets.com/stock/CLDN/news

Current Share Structure:

Outstanding shares as of October 31, 2015 was 23,916,021

Authorized shares as of October 31, 2015 was 200,000,000

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10999416

About the Proposed Merger

Existing Eiger stockholders as well as investors in the contemporaneous financing will receive newly issued shares of Celladon common stock in connection with the proposed merger. Celladon is expected to issue approximately 85.0 million new shares of its common stock to Eiger stockholders and participants in the financing. On a pro forma basis for the combined company, current Celladon shareholders are expected to own approximately 22%, current Eiger shareholders approximately 45% and the new Eiger investor syndicate approximately 33%, each on a fully-diluted basis.

The transaction has been unanimously approved by the boards of directors of both companies, and a majority of Eiger stockholders have agreed to vote in favor of the transaction. The proposed merger is expected to close in the first half of 2016, subject to the approval of the stockholders of each company as well as regulatory approval and other customary conditions. The merger agreement contains further details with respect to the proposed merger.

Celladon’s exclusive financial advisor in the transaction is Wedbush PacGrow Healthcare. Jefferies LLC is acting as lead financial advisor to Eiger and Piper Jaffray is acting as financial advisor. Pillsbury Winthrop Shaw Pittman LLP served as legal counsel to Celladon and Cooley LLP served as legal counsel to Eiger.

Chart